Skip to contentpdufa.bio

LX2020

Page updated ·next FDA decision on the calendar ·Data as of Nov 19, 2026 12:24 AM ET

LX2020 is a Lexeo Therapeutics, Inc. program. Its next catalyst is a Readout in Dec 2026.

LXEO catalyst hub

All upcoming FDA decision dates on the 2026 PDUFA calendar

About this program

Sponsor: Lexeo Therapeutics, Inc. (LXEO). We track 1 catalyst event for this program: 1 upcoming and 0 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.

Catalyst history

Readout · Dec 2026LXEO

Specialist biotech funds holding LXEO, 13F for the quarter ended September 30, 2026

FundSharesValue at quarter endFiling
RA Capital Management5,000,000$16.9 millionfiled November 16, 2026
OrbiMed Advisors3,203,050$10.8 millionfiled November 16, 2026
Avoro Capital Advisors525,000$1.8 millionfiled November 16, 2026
RTW Investments239,149$808,324filed November 16, 2026

13F reports list long positions in common stock at quarter end, are due 45 days later, and show no short positions or later trades. Notes, warrants and other instruments are not counted as shares.

Questions

When is LX2020's next FDA decision or readout?

The next tracked catalyst for LX2020 is a Readout in Dec 2026.

What happened at LX2020's most recent FDA decision?

No FDA decision for LX2020 is in our archive yet.

Who makes LX2020?

Lexeo Therapeutics, Inc. (LXEO).

Where does this data come from?

FDA announcements, sponsor press releases and SEC filings. Each FDA decision links its own page, which names its source or says plainly that it has none.